22 May 2019 - AV001 granted priority review.
Avadel Pharmaceuticals today announced that the U.S. FDA has accepted the new drug application for the Company’s fourth hospital product, AV001.
The FDA has assigned a Prescription Drug User Fee Act target action date of 15 September 2019.